Anke Lange-Schlenska

Regensburg, BY, DE 
Regensburg, BY, DE 

Overview

Anke Lange-Schlenska practices practicing medicine in Regensburg, Germany.

Her clinical expertise encompasses Colorectal Cancer and Cholangiocarcinoma (Bile Duct Cancer).

She is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Regensburg, BY, Germany
Other Locations
Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2026
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) A Multicenter, Prospective, Cohort Study To Assess The Genomic Profiles And Associated Therapy Decision In Gastrointestinal Cancer
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) A Multicenter, Prospective, Cohort Study To Assess The Genomic Profiles And Associated Therapy Decision In Gastrointestinal Cancer
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
View 2 Less Clinical Trials

13 Total Publications

Reassessing the role of CEA in the treatment of rectal cancer in the era of TNT.
Reassessing the role of CEA in the treatment of rectal cancer in the era of TNT.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026

Frequently Asked Questions about Anke Lange-Schlenska

Is Anke Lange-Schlenska a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Anke Lange-Schlenska is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anke Lange-Schlenska participate in research or clinical trials?

Yes. Anke Lange-Schlenska has published 13 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Anke Lange-Schlenska's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lange-Schlenska's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile